Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Botanix Pharmaceuticals Ltd. is a specialty pharmaceutical company focusing on the research, development, and commercialization of novel dermatology therapies and antimicrobial products. The primary function of the company is to address significant unmet medical needs in dermatology, with an emphasis on conditions such as primary axillary hyperhidrosis, serious acne, atopic dermatitis, and various skin infections. Botanix’s product pipeline includes both proprietary and in-licensed compounds; its lead product, Sofdra, has received FDA approval for treating excessive underarm sweating, while other candidates like BTX 1503, BTX 1801, and BTX 1702 target acne, staphylococcal infections, and rosacea, respectively. Operating primarily between Australia and the United States, Botanix leverages advanced drug formulation and delivery technologies to create effective transdermal therapies. The company’s presence in high-need therapeutic areas and its ability to progress assets from development through regulatory approval position it as a notable innovator within both the pharmaceuticals and biotechnology sectors. Botanix plays an important role in expanding treatment options for dermatology patients globally while contributing to innovation in the pharmaceutical market.